| Cash Flow | 2025-06-30 |
|---|---|
| Share based compensation | 7,828 |
| Net loss and comprehensive loss | -36,550 |
| Prepaid expenses and deposits | -483 |
| Incentive and tax receivables | -1,629 |
| Accrued liabilities | -906 |
| Accounts payable | -2,887 |
| Gain on settlement of accounts payable | 0 |
| Deferred grant income | 37 |
| Net cash used in operating activities | -30,440 |
| Proceeds from exercise of stock options | 1,679 |
| Payment for taxes related to cashless exercise of options | -2,262 |
| Issuance of common shares | 0 |
| Net cash (used in) provided by financing activities | -583 |
| Decrease in cash and cash equivalents during the period | -31,023 |
ANAVEX LIFE SCIENCES CORP. (AVXL)
ANAVEX LIFE SCIENCES CORP. (AVXL)